144 related articles for article (PubMed ID: 38641485)
1. Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions.
Gallucci Figorelle L; Galvão PT; de Lima FMR; Marimon P; Pentagna N; Milito C; Schaffel R; Carneiro K
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38641485
[TBL] [Abstract][Full Text] [Related]
2. SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?
Li S; Tang G; Jain P; Lin P; Xu J; Miranda RN; Cheng J; Yin CC; You MJ; Wang ML; Medeiros LJ
Mod Pathol; 2024 Feb; 37(2):100405. PubMed ID: 38104893
[TBL] [Abstract][Full Text] [Related]
3. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
4. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
Condoluci A; Rossi D; Zucca E; Cavalli F
Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
[TBL] [Abstract][Full Text] [Related]
5. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
6. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
7. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.
Yatabe Y; Suzuki R; Tobinai K; Matsuno Y; Ichinohasama R; Okamoto M; Yamaguchi M; Tamaru J; Uike N; Hashimoto Y; Morishima Y; Suchi T; Seto M; Nakamura S
Blood; 2000 Apr; 95(7):2253-61. PubMed ID: 10733493
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression.
Zeng W; Fu K; Quintanilla-Fend L; Lim M; Ondrejka S; Hsi ED
Am J Surg Pathol; 2012 Feb; 36(2):214-9. PubMed ID: 22251940
[TBL] [Abstract][Full Text] [Related]
9. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
[TBL] [Abstract][Full Text] [Related]
10. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S
Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350
[TBL] [Abstract][Full Text] [Related]
11. A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior.
Kurita D; Takeuchi K; Kobayashi S; Hojo A; Uchino Y; Sakagami M; Ohtake S; Takahashi H; Miura K; Iriyama N; Sugitani M; Miyoshi H; Hatta Y; Ohshima K; Takei M
Virchows Arch; 2016 Oct; 469(4):471-6. PubMed ID: 27457074
[TBL] [Abstract][Full Text] [Related]
12. The pathologic diagnosis of mantle cell lymphoma.
Li S; Xu J; You MJ
Histol Histopathol; 2021 Oct; 36(10):1037-1051. PubMed ID: 34114641
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
Jing C; Zheng Y; Feng Y; Cao X; Xu C
Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
[TBL] [Abstract][Full Text] [Related]
14.
Martín-Garcia D; Navarro A; Valdés-Mas R; Clot G; Gutiérrez-Abril J; Prieto M; Ribera-Cortada I; Woroniecka R; Rymkiewicz G; Bens S; de Leval L; Rosenwald A; Ferry JA; Hsi ED; Fu K; Delabie J; Weisenburger D; de Jong D; Climent F; O'Connor SJ; Swerdlow SH; Torrents D; Beltran S; Espinet B; González-Farré B; Veloza L; Costa D; Matutes E; Siebert R; Ott G; Quintanilla-Martinez L; Jaffe ES; López-Otín C; Salaverria I; Puente XS; Campo E; Beà S
Blood; 2019 Feb; 133(9):940-951. PubMed ID: 30538135
[TBL] [Abstract][Full Text] [Related]
15. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Chiarle R; Budel LM; Skolnik J; Frizzera G; Chilosi M; Corato A; Pizzolo G; Magidson J; Montagnoli A; Pagano M; Maes B; De Wolf-Peeters C; Inghirami G
Blood; 2000 Jan; 95(2):619-26. PubMed ID: 10627471
[TBL] [Abstract][Full Text] [Related]
16. Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases.
Yatabe Y; Suzuki R; Matsuno Y; Tobinai K; Ichinohazama R; Tamaru J; Mizoguchi Y; Hashimoto Y; Yamaguchi M; Kojima M; Uike N; Okamoto M; Isoda K; Ichimura K; Morishima Y; Seto M; Suchi T; Nakamura S
Pathol Int; 2001 Oct; 51(10):747-61. PubMed ID: 11881727
[TBL] [Abstract][Full Text] [Related]
17. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma.
Izban KF; Alkan S; Singleton TP; Hsi ED
Arch Pathol Lab Med; 2000 Oct; 124(10):1457-62. PubMed ID: 11035575
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and prognosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL).
Asaad NY; Abd El-Wahed MM; Dawoud MM
J Egypt Natl Canc Inst; 2005 Dec; 17(4):279-90. PubMed ID: 17102815
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
[TBL] [Abstract][Full Text] [Related]
20. CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases.
Xu J; Medeiros LJ; Saksena A; Wang M; Zhou J; Li J; Yin CC; Tang G; Wang L; Lin P; Li S
Oncotarget; 2018 Feb; 9(14):11441-11450. PubMed ID: 29545910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
